-$0.91 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter

Equities research analysts expect Audentes Therapeutics Inc (NASDAQ:BOLD) to report earnings per share (EPS) of ($0.91) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Audentes Therapeutics’ earnings, with estimates ranging from ($1.02) to ($0.84). Audentes Therapeutics reported earnings per share of ($0.82) during the same quarter last year, which indicates a negative year over year growth rate of 11%. The company is expected to issue its next earnings report on Thursday, March 14th.

On average, analysts expect that Audentes Therapeutics will report full year earnings of ($3.38) per share for the current fiscal year, with EPS estimates ranging from ($3.60) to ($2.99). For the next financial year, analysts forecast that the firm will report earnings of ($3.86) per share, with EPS estimates ranging from ($4.53) to ($3.18). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.09). During the same quarter in the previous year, the company posted ($0.88) earnings per share.

Several equities research analysts have recently weighed in on the company. HC Wainwright set a $33.00 price target on Audentes Therapeutics and gave the company a “buy” rating in a research report on Sunday, October 14th. William Blair cut Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 6th. Wedbush reiterated an “outperform” rating and set a $49.00 price target on shares of Audentes Therapeutics in a research report on Wednesday, August 8th. ValuEngine cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 12th. Finally, Mizuho upgraded Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Audentes Therapeutics has an average rating of “Hold” and a consensus price target of $35.49.

In other news, Director Louis G. Lange sold 33,000 shares of the business’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $37.38, for a total transaction of $1,233,540.00. Following the completion of the transaction, the director now owns 365,999 shares of the company’s stock, valued at $13,681,042.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 12,952 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $40.00, for a total value of $518,080.00. Following the transaction, the chief executive officer now directly owns 12,952 shares of the company’s stock, valued at approximately $518,080. The disclosure for this sale can be found here. Insiders have sold 101,039 shares of company stock valued at $3,465,020 in the last three months. 6.60% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Partner Investment Management L.P. purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $162,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $226,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $231,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $232,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $332,000. 84.48% of the stock is owned by institutional investors.

Shares of BOLD traded down $0.38 during midday trading on Friday, hitting $24.07. 500 shares of the company traded hands, compared to its average volume of 638,123. Audentes Therapeutics has a one year low of $19.62 and a one year high of $46.18. The stock has a market cap of $1.04 billion, a PE ratio of -7.18 and a beta of 1.91.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: How does inflation affect different investments?

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit